Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ra-223 Dichloride in Osteosarcoma
NCT01833520Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2013
- Primary completion
- Apr 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in osteosarcoma (OS), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2013; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT01833520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833520.